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• Parental-reported question on asthma ever can function as a proxy for asthma medication and 26 
diagnosis in research  27 
• Parental-reported current asthma has good agreement with register-based records in the last 18 28 
months 29 
 30 
Word count:  3081 31 
 32 
Abstract 33 
Purpose: Risk factors and consequences of asthma can be studied using validated questionnaires. The 34 
overall objective of this study was to assess the agreement of parental-reported asthma related 35 
questions regarding their children against Swedish health care registers.  36 
Methods: We linked a population-based twin cohort of 27,055 children aged 9-12 years, to the Swedish 37 
Prescribed Drug Register, National Patient Register and the Primary care register. Parent-reported 38 
asthma was obtained from questionnaires and diagnoses and medication were retrieved from the 39 
registers. For the agreement between the questionnaire and the registers, Cohen’s kappa was estimated. 40 
Results The kappa of the ‘reported ever asthma’ against a ‘register-based ever asthma’ was 0.69 and 41 
0.57 between the parental-‘reported doctor’s diagnosis’ and ‘register-based doctor’s diagnosis’ ’. The 42 
highest agreement between ‘reported current asthma’ and ‘register- based current asthma’ with at least 43 
one dispensed medication or a diagnosis applied to different time-windows was seen for an 18 month 44 
window (kappa=0.70).  45 
Conclusions We found that parent-reported asthma-related questions showed on average good 46 
agreement with the Swedish health care registers. This implies that in depth questionnaires with rich 47 
information on phenotypes are suitable proxies for asthma in general and can be used for health care 48 
research purposes.  49 
 50 
 51 
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Introduction 52 
 53 
To study risk factors and consequences of asthma, validated instruments for defining asthma in studies 54 
using registers, clinical cohorts and questionnaires are needed. Numerous efforts have been made to 55 
ensure that specific questionnaires detecting asthma are standardized, repeatable and can be applied 56 
consistently across a range of geographical and cultural settings (1, 2). Both the European Community 57 
Respiratory Health Survey (1) and the International Study on Asthma and Allergies in Childhood (ISAAC) 58 
(2) were developed, where possible, from pre-existing published questionnaires, where validity had been 59 
previously assessed (3, 4). 60 
Several studies have validated questions on ‘reported ever asthma’ (5-7) and symptom-based outcomes 61 
(e.g., wheeze, waking at night, coughing) (8-11), whereas others have focused on doctor’s diagnosis (6) 62 
or taking asthma medication (6) . Other examples of asthma validation studies include symptoms-based 63 
questions against; clinical evaluations (5, 8), structured interviews (12) and patient records of a diagnosis 64 
(13). The standardized ISAAC questionnaire (2) has a specific question on ‘reported ever asthma’ for 65 
which validity in other countries has been assessed (5, 7) but not in Sweden. In addition, to our 66 
knowledge, no study has assessed the validity of the questions describing  ‘reported current asthma’ and 67 
doctor’s diagnosis from the ISAAC questionnaire. Furthermore, timing of dispenses has been investigated 68 
in a previous study in which agreement between reported and prescribed asthma medication was 69 
highest within an 18-months window (14).  70 
Questionnaire studies are relatively low cost, time-efficient, and permit large sample sizes compared to 71 
clinical data collections (15, 16). On the other hand, questionnaires are often restricted to specific age 72 
groups or specific areas, which can reduce generalizability to other populations (17, 18). Identifying 73 
affected individuals often involves retrospective questioning about doctor’s diagnosis and previous 74 
symptoms, therefore subject to recall bias (19, 20). By using population-based register data for asthma 75 
diagnoses and prescriptions, the data are objective and some of the aforementioned errors can be 76 
avoided particularly if the coverage of the register is high. 77 
The overall objective for this study was to assess the agreement between parental-reported childhood 78 
asthma questions from the nationwide twin cohort Childhood and Adolescent Twin Study in Sweden 79 
(CATSS) and population-based Swedish health care registers (National Patient Register, NPR, which 80 
contains all inpatient diagnoses and 75-80% of all outpatient diagnoses since 1987 and 2001 respectively, 81 
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Swedish Prescribed Drug Register, SPDR, which contains all prescribed medications that are dispensed at 82 
Swedish pharmacies and Stockholm regional health care data warehouse, VAL, which holds all primary 83 
care diagnoses from Stockholm county). Our first aim was to assess the agreement between ‘reported 84 
ever asthma’ and a ‘register-based ever asthma’ algorithm (21) (at least 2 dispenses of asthma 85 
medication or an asthma diagnosis) using SPDR and NPR and between ‘reported doctor’s diagnosis’ and 86 
‘register-based doctor’s diagnosis’ from NPR and VAL. Our second aim was to assess the agreement 87 
between ‘reported asthma medications’ and ‘register-based asthma medications’, with the 88 
corresponding data within different time windows in the registers.  89 
 90 
Method 91 
Study population 92 
This study included children participating in CATSS (22). CATSS is an ongoing longitudinal twin study 93 
targeting all twins born in Sweden since July 1st, 1992 with an overall response rate of 76% until 2012. 94 
Since 2004, in connection to the twin’s 9th or 12th birthdays, parents are interviewed via telephone 95 
regarding the children’s somatic, social and mental health (22). CATSS is linked to the Swedish health 96 
care registers, NPR, SPDR and VAL. The study was approved by the Regional Ethical Review Board in 97 
Stockholm, Sweden. Informed consent was obtained. 98 
 99 
Study design and data sources 100 
This is an agreement study comparing parental interview answers with data from registers where no 101 
measure was considered gold standard(23). Several national health care registers are held by the 102 
Swedish National Board of Health and Welfare such as the SPDR (24) and NPR (25). The SPDR contains 103 
the Anatomical Therapeutic Chemical [ATC]-codes, date, number of packages, and when possible, daily 104 
defined doses) and age, sex and PIN of the patient since July 2005. Information on primary and 105 
secondary diagnoses according to the International Classification of Diseases 10th revision (ICD -10) is 106 
included in the NPR since 1997. All data were de-identified prior to analyses and kept on a secure server. 107 
Linking data from multiple registers is made possible through the Swedish unique personal identity 108 
number (PIN) (26). 109 
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 110 
Sub-cohorts 111 
The full cohort consisted of N=27,055 twins that were interviewed up until the end of 2012. From this 112 
population we derived two sub-cohorts. The first sub-cohort, the National cohort, consisted of twins 113 
whose parents had completed the interview since July 1st 2006 (n=18,725). This date was selected 114 
because July 1st 2005 was the date that the SPDR was established, covering the whole Swedish 115 
population.  By selecting this date we were able to retrospectively collect information on dispensed 116 
medication from the SPDR for at least one year to assess ‘register-based ever asthma’.  The second sub-117 
cohort, the Stockholm cohort, included twins that were born from 2001 and who had been living in 118 
Stockholm all years between birth and the interview (n=2,226).  This subgroup of twins was selected 119 
since information on both specialist (NPR) and primary care was available for Stockholm County from 120 
2003 by the VAL registry. The reason we selected individuals born from 2001 was because a child with 121 
asthma before the age of two years usually comes in contact with the specialist care and gets a diagnosis 122 
in the National Patient Register (NPR).  123 
 124 
 125 
Measures of ever and current asthma in the National cohort 126 
We defined a ‘reported ever asthma’ case as a child with a positive answer to the question ’Does he/she 127 
have, or has he/she had asthma?’ Everyone that replied positive was then directed to other asthma 128 
related questions (see Panel 1). ‘Reported current asthma’ was then defined as reporting positively to 129 
the question ’Does he/she still have asthma?’.  130 
The ‘register-based ever asthma’ algorithm based on SPDR and NPR data has been previously described 131 
and validated (21). The age-specific positive predicted value (PPV) from that validation study was 0.89 132 
(95% CI: 0.85-0.92) for ages between 4.5-17 years. In brief, the ‘register-based ever asthma’ is defined as 133 
either: 1) asthma medication of ≥ 2 dispenses of ICS (inhaled corticosteroid, ATC code: R03BA) and/or 134 
LTRA (leukotriene receptor agonist, ATCcode: R03DC03) and/or b2-ICS (combination of inhaled beta-2 135 
agonist and inhaled corticosteroid, ATCcodes: R03AK06 and R03AK07) independent of time between,  136 
and/or  2) ≥ 3 dispenses of ICS and/or LTRA and/or b2-ICS and/or b2 (inhaled beta-2 agonist, ATC code: 137 
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R03AC) within a 12-month period (prior to the date of the interview) or 3) an asthma diagnosis (ICD-10 138 
diagnostic codes:  J45, and J46) from NPR. 139 
To define ‘register-based current asthma’ from the SPDR we used the same register-based algorithm as 140 
for ‘register-based ever asthma’ (21) in combination with conditions placed on recent time-windows for 141 
asthma diagnosis (ICD-10 diagnostic codes:  J45, and J46) from NPR respectively in the last 6, 12, 18 and 142 
24 months prior to the date of the interview. Instead of a recent diagnosis we also conditioned on at 143 
least one dispensed medication (ICS, LTRA, B2, b2-ICS) from the SPDR. We wanted to investigate several 144 
time windows to see which one captured the ‘reported current asthma’ question best and to evaluate if 145 
it would be enough using only dispensed medication. 146 
 147 
Measures of a doctor’s diagnosis in the Stockholm cohort 148 
A parental-‘reported doctor’s diagnosis’ was defined as answering ‘yes’ to the asthma gated question 149 
(‘reported ever asthma’) plus answering ‘yes’ to: ’You said that he/she has or has had asthma, has 150 
he/she been given that diagnosis by a doctor or nurse?’  151 
‘Register-based doctor’s diagnosis’ was defined based on at least one primary or secondary diagnosis of 152 
asthma up until the time of the interview by ICD-10 codes (J45, and J46) from NPR (inpatient or 153 
outpatient) or VAL (primary care). 154 
 155 
Measures of asthma medications in the National cohort 156 
Parental-‘Reported asthma medications’ was defined as answering ‘yes’ to the asthma gated question 157 
plus answering ‘yes’ to the following question: ’Does your child  currently take any asthma-medication 158 
(inhalator, spray or tablets)?’ This question was added in 2010 as an update to the original 159 
questionnaire, so not included for everyone (n=9860). 160 
‘Register-based asthma medications’ was defined as at least one dispensed asthma medication (ICS, 161 
LTRA, b2, b2-ICS) from SPDR during the last , 6, 12, 18 and 24 months prior to the interview.  162 
 163 
Statistical analyses 164 
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Agreement between register data and questionnaire data was assessed, using Cohen’s kappa statistic, 165 
with 95% Confidence Interval (CI). The percentage of overall agreement was also estimated. Cohen’s 166 
kappa is a measure of agreement beyond what would be expected by pure randomness. A kappa over 167 
0.75 is characterized as excellent, a kappa of 0.40-0.75 is considered fair to good, and 0.40 and below as 168 
poor (27). 169 
Statistical Analysis Software 9.4 (SAS Institute, Cary, NC) was used for all analyses.  170 
 171 
Results 172 
Table 1 lists the demographic characteristics of the sub-cohorts of the CATSS study; the National and 173 
Stockholm cohorts. In general, the characteristics of the smaller Stockholm cohort were very similar to 174 
the much larger National cohort. The prevalence of ‘reported ever asthma’ was slightly higher in the 175 
Stockholm cohort (17.4%), compared to the national cohort (14.5%). However, ‘reported current 176 
asthma’ (7.1%) did not differ substantially between cohorts.  177 
 178 
‘Reported ever asthma’ 179 
The kappa statistic of ‘reported ever asthma’ and ‘register-based ever asthma’ was 0.69, indicating good 180 
agreement. The overall agreement was 92.1% (Table 2).  181 
 182 
Doctor’s diagnosis 183 
The comparison between the parental ‘reported doctor’s diagnosis’ and the ‘register-based doctor’s 184 
diagnosis’ from NPR or VAL showed a kappa of 0.57, indicating a fair to good agreement. The overall 185 
agreement was 86.3% (Table 2).  186 
 187 
’Current Asthma’ 188 
8 
 
Table 3 shows the agreement between ‘reported current asthma’ and ‘register-based current asthma’ 189 
with time-specific criteria for at least one dispensed medication or diagnosis within four different time-190 
windows. For 6 months the kappa statistic was 0.59, 0.67 and 0.70 for 12 and 18 months respectively 191 
and 0.70 for 24 months. When diagnosis was removed from the ‘reported current asthma’ definition the 192 
agreement just slightly decreased for all of the time-windows with a kappa of 0.56, 0.65, 0.69 and 0.69 193 
respectively. At all time-windows the overall agreement was very high (95% to 96%).  194 
 195 
Taking asthma medications 196 
Table 4 shows the agreement between ‘reported asthma medications’ by parent and ‘register-based 197 
asthma medications’, any asthma medication dispensed from SPDR in different time-windows. The 198 
kappa increased from 0.52 for 6 months before the interview to 0.57 for 12 months and then slightly 199 
increased for 18 months before the interview to 0.59. For a time-window of 24 months the kappa 200 
decreased to 0.55. The overall agreement ranged between 78-80%.  201 
 202 
Discussion 203 
We found good agreement between ‘reported ever asthma’ and ‘register-based ever asthma’ 204 
(kappa=0.69) and fair to good agreement (kappa=0.57) between parental-‘reported doctor’s diagnosis’ 205 
and ‘register-based asthma diagnosis’. We also found good agreement (kappa= 0.70) between ‘reported 206 
current asthma’ and ‘register-based current asthma’, conditional on at least one dispensed medication 207 
or a diagnosis within the last 18-months. Finally, we found the best agreement between ‘reported 208 
asthma medications’ by parents and ‘register-based asthma medications’ within the last 18 months 209 
(kappa=0.59). 210 
. 211 
Previous and similar studies that assessed the validity of the question on ‘reported ever asthma’ against 212 
a clinical diagnosis found high sensitivity (i.e., proportion with a diagnosis that are correctly identified as 213 
such), 0.87 in one study (7) and good sensitivity, 0.68, in another one (28). Valle et al. used a younger 214 
cohort than ours, 6-7 years old children and they used a golden standard (i.e., clinical diagnosis) which 215 
could potentially explain why they found a high estimate of sensitivity (0.87)  (7). Marco et al. 216 
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investigated adults and found good validity (sensitivity of 0.68) while we studied children and found 217 
good agreement  (kappa =0.69) (28). In addition, among university students the question on ‘reported 218 
ever asthma’ was validated against a variable combining physician’s interview, methacholine challenge, 219 
skin prick test and specific IgE which reported a low sensitivity (0.40) and a good PPV (0.76) (5). Thus, 220 
large heterogeneity in terms of sensitivity, PPV and Kappa exists between the different studies (age-221 
groups and comparison variables) when assessing the validity of ‘reported ever asthma’ from a 222 
questionnaire.   223 
We have previously validated the register based comparison variable ‘register-based ever asthma’ 224 
against medical records with high positive predictive values (0.89 95% CI: 0.85-0.92) for clinical asthma 225 
diagnosis (21). This definition of asthma has been applied in several studies as a proxy for ever/incident 226 
asthma (29-33) as well as for current/prevalent asthma (30).. Another study investigating ‘reported 227 
doctor’s diagnosis’ found a moderate PPV of 0.57 when the question of parental-reported doctor’s 228 
diagnosis was validated against asthma medication reimbursement in a younger cohort (6) . The 229 
question of doctor’s diagnosis has also been validated against a structured interview among 7-8 years old 230 
which found excellent PPV (0.98) and good sensitivity (approx. 0.70) (12). There are many reasons to our 231 
fairly low kappa estimate, for example asthma diagnosis in low ages is fairly unspecific and those who 232 
answered no to the question on ‘reported ever asthma’ never got the question on doctor’s diagnosis 233 
(see Figure 1). In addition, the kappa could be due to both over-(the register may not have coverage)  234 
and underreporting since a diagnosis given a long time ago may be forgotten if the child has no current 235 
asthma symptoms or medication. However, this does not imply per se that our comparison variable is 236 
poor. 237 
We estimated the agreement between ‘reported current asthma’ and ‘register-based current asthma’ 238 
with different time windows. We found the 18-month window to be preferable with a kappa of 0.70, 239 
which indicates a good agreement. Interestingly, when only using medication data the resulting kappa 240 
just decreased slightly giving us confidence that our ‘register-based current asthma’ including one 241 
recently dispensed medication  is almost as good a proxy for ‘reported current asthma’ as when using 242 
both medication and diagnosis. Recall bias has shown not to be influential within the last 12 months in a 243 
recent study of self-reported hospital admissions compared to administrative records (34). In light of 244 
this, it is not surprising that reported ‘current’ asthma (with no timeframes in the question) equals ‘in the 245 
last 18 months’. Possible explanations could be purchasing large amounts of medicines irregularly, 246 
having mild asthma which does not require medications or sharing medicines with other family members 247 
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(14). We were unable to find any other studies that had assessed the validity of ‘reported current 248 
asthma’. Current wheeze is more common to validate in childhood than current asthma, for example 249 
current wheeze (or wheezing symptoms within the last 12 months) is included in the ISAAC 250 
questionnaire and applied in other validation studies (6, 7). However, wheeze is a symptom and asthma 251 
is a condition/disease and children with wheeze do not necessarily need to have asthma. Therefore 252 
those studies using ‘current wheeze’ are limited in generalizing their findings to asthma.  253 
We found a fair agreement between ‘reported asthma medications’ and ‘register-based asthma 254 
medications’ with a kappa ranging from 0.52 to 0.59 depending on time-window. Nwaru et al. validated 255 
a question on parental-reported asthma medication during the last 12 months against the asthma 256 
medication reimbursement and reported excellent sensitivity and perfect NPV (6). One difference 257 
between our study and that of Nwaru et al. was that their question included a clear time-window, while 258 
ours was vaguer and left it to the parents to interpret the meaning of ‘current’. Koster et al., 2010 found 259 
substantial agreement between parental reported ICS use and pharmacy register based ICS use (35). 260 
Their study also had an explicit time-period (i.e., 12 months) and differences in prevalence compared to 261 
our study, which affects the kappa. We rather chose to estimate agreement between the answers and 262 
register-based information on dispensed medications within four different time frames and we found 18 263 
months to have the best agreement. Importantly, the same time-window of 18 months was found 264 
preferable in a previous study on the concordance between register data on dispensed drugs and 265 
parental-reported use of asthma drugs in adolescents (14). If all patients had complied with the 266 
prescribed treatment, we would probably have an even better register-based measure of asthma, which 267 
would be more in agreement with the questionnaire information on whether the child have asthma or 268 
not. 269 
 270 
Strengths and limitations 271 
The CATSS study has nationwide coverage and high response rate which strengthen the generalizability 272 
of the findings and decrease possible selection bias. Another strength is that data are retrieved from the 273 
Swedish health care registers. Register data enable us to obtain an objective measure based on 274 
dispensed medication from the SPDR and diagnoses from the NPR. In addition, in Stockholm County, 275 
primary health care centers (PHCC) have reported all diagnostic information (ICD-codes) to VAL since 276 
2003. Therefore we restricted the Stockholm cohort to only include those who were born and lived in 277 
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Stockholm all years (and not just temporary). One could argue that being a twin may affect the 278 
generalizability of the findings. However, it has been shown in the age-range between 5 to 18 years that 279 
the prevalence of asthma is not higher in twins compared to singletons (30). Therefore, including twins 280 
should not affect the generalizability of the findings.  Another limitation is the smaller sample size for 281 
‘reported asthma medications’, as this question was added to the interviews in year 2010. In addition, 282 
young children with wheeze and shortness of breath might not always end up with an asthma diagnose 283 
by a doctor, therefore there may be some under-representation in the parental-reported ‘ever asthma’. 284 
We were not able to capture those children and their symptoms in the current study. Furthermore, 285 
although a binary measure of asthma is very common in registers and questionnaire based-studies, we 286 
recognize that a binary outcome does not accurately represent the heterogeneity of asthma phenotypes 287 
and persistence. However, since register-based outcomes for asthma are used widely in the Nordic 288 
countries and other countries such as Canada, USA and Korea we felt it was important to test the 289 
agreements of commonly used binary outcomes. Registers have the advantages of being cost-effective 290 
and are population-based therefore improving generalizability and statistical power. In depth 291 
questionnaire-based cohort studies can provide more information on the various asthma phenotypes 292 
important for clinical applications but can suffer from recall-bias and are often smaller hence providing 293 
less power for epidemiological questions, and may be less generalizable. 294 
 295 
Conclusions 296 
We found that parent-reported asthma-related questions showed on average good agreement with the 297 
Swedish health care registers which can be applied for health care research purposes. Valid screening 298 
instruments such as questionnaires, registers, clinical cohorts and patient charts can improve 299 
epidemiological research to address various questions on risk factors and consequences of asthma. 300 
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Panel 1. Figure of the asthma related questions from the questionnaire 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
 424 
 425 
 426 
• ‘Reported ever asthma’: ’Does he/she have or has he/she had asthma’? 
          if ’yes’ then:   
•  ‘Reported current asthma’: ’Does he/she still have asthma’? 
•  ‘Reported doctor’s diagnosis’:  ’You said that he/she has or has had asthma, 
has he/she been given that diagnosis by a doctor or nurse’? 
•  ‘Reported asthma medications’: ’Does your child currently take any asthma 
medication (inhalator, spray or tablets)’?  
15 
 
 427 
 428 
 429 
Table 1. Participants' characteristics in the two cohorts 430 
 
Category 
National Cohort* 
(n=18725) 
Stockholm Cohort # 
(n=2226) 
Age at interview (mean± 
SD[range]); years  9.4±1.0 [8.5-12.6] 9.2±0.4 [8.5-11.5] 
Classified as 9 years old n (%)  16561 (88.4) 2226 (100) 
Sex Male  9495 (50.7) 1158 (52.0) 
 Female 9230 (49.3) 1068 (48.0) 
'Reported ever asthma' from 
questionnaire No 15866 (84.7) 1822 (81.9) 
 Yes 2720 (14.5) 388 (17.4) 
 Missing 139 (0.7) 16 (0.7) 
'Reported current asthma' 
from questionnaire No  17324 (92.5) 2059 (92.5) 
 Yes 1329 (7.1) 158 (7.1) 
 Missing 72 (0.4) 9 (0.4) 
‘Reported doctor's 
diagnosis’ from 
questionnaire No 16071 (85.8) 1846 (82.9) 
 Yes 2484 (13.3) 360 (16.2) 
 Missing 170 (0.9) 20 (0.9) 
‘Reported asthma 
medications’ from 
questionnaire (current)§ No  917 (9.3) 254 (11.4) 
 Yes 492 (5.0) 116 (5.2) 
 Missing 8451 (85.7) 1856 (83.4) 
‘Register-based ever asthma’ 
Asthma defined5 by 
dispensed medications from 
SPDR1 and/or a diagnosis 
from NPR2 No 15398 (82.2) 1731 (77.8) 
 Yes 2831 (15.1) 496 (21.1) 
 Missing 496 (2.63) 26 (1.2) 
‘Register-based asthma 
medications’ Any asthma 
medications dispenses ever 
from SPDR1 No 14752 (78.8) 1655 (74.3) 
 Yes 3973 (21.2) 571 (25.7) 
Any asthma diagnoses from 
NPR2 ever No 16203 (86.5)  
 Yes 2522 (13.5)  
‘Register-based doctor’s 
diagnosis’ Any asthma 
diagnoses from NPR2 or VAL3 
ever No  1704 (76.6) 
 Yes  522 (23.5) 
Age at first diagnose (mean± 
SD); years   4.0 (3.8) 3.8 (3.6) 
16 
 
SES (Socio Economic Status) 
from LISA4 9 y completed 294 (1.6) 42 (1.9) 
 
10-12 y 
completed 7278 (38.9) 554 (24.9) 
 
>12 y 
completed 10907 (58.3) 1594 (71.6) 
 Missing 246 (1.3) 36 (1.6) 
Answered questionnaire 
(mother/father/other) 
Biological 
mother 15827 (84.5) 1818 (81.7) 
Migrant background (Mother 
or father born outside 
Scandinavia)  
No 16421 (87.70) 1808 (81.22) 
 Yes 2188 (12.23) 400 (17.97) 
 Missing 116 (0.07) 18 (0.81) 
 
Biological 
father 2812 (15.02) 382 (17.2) 
 Other 86 (0.5) 26 (1.2) 
 Missing 0 0 
*National cohort included twins in CATSS, whose parents completed the telephone interview since July 1st 2006. 431 
#Stockholm cohort included twins in CATSS, born from 2001 in Stockholm and lived all years in Stockholm 432 
§ This question was added in 2010, in total n=9860 answered the questionnaire after this time-point 433 
1=Swedish Prescribed Drug Register (SPDR) 434 
2=National Patient Register (NPR) 435 
3=Stockholm regional health care data warehouse (VAL) 436 
4=Longitudinal integration database for health insurance and labor market studies (LISA) at the year when children were 5 years  437 
5=Asthma medication of ≥ 2 dispenses of ICS and/or LTRA and/or B2-ICS independent of time between and/or ≥ 3 dispenses of 438 
ICS and/or LRTA and/or B2-ICS and/or B2 within a 12 month period (prior to the date of the interview) and/or a diagnosis from 439 
NPR 440 
 441 
 442 
 443 
Table 2. Agreement between ‘reported ever asthma’ and ‘reported doctor’s diagnosis’ from the 444 
questionnaire against SPDR, NPR and VAL in the National and the Stockholm cohort respectively. 445 
Questionnaire,  
q Registers,  r 
Overall 
agreement %(n) 
q+r-  
n 
q-r+ 
n 
q+r+  
n 
q-r-  
n Kappa, (95% CI) 
National cohort 
(n=18725) 
 
       
 'Reported ever 
asthma' 
(questionnaire) 
‘Register-
based ever 
asthma’, 
Asthma 
defined by 
dispensed 
medications 
(SPDR) a or a 
diagnosis 
from NPR 
92.09 
(16675/18107)  646 786  2003  14672 0.69     (0.68-0.71) 
Stockholm 
Cohort 
(n=2226)  
 
‘Register-
based 
doctor’s 
diagnosis’, 
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 ‘Reported 
doctor's 
diagnosis’ 
(questionnaire) 
Any asthma 
diagnosis 
from NPR or 
VAL 
86.31      
(1904/2206) 78  224 282 1622 0.57     (0.53-0.61) 
Table 2 shows the National cohort and the number of participants who were either positive or negative on the questionnaire 446 
variable, q+ and q- respectively and positive or negative on the register variable, r+ and r- respectively.  447 
a=Asthma medication of ≥ 2 dispenses of ICS and/or LTRA and/or B2-ICS independent of time between and/or ≥ 3 dispenses of 448 
ICS and/or LRTA and/or B2-ICS and/or B2 within a 12 month period (prior to the date of the interview)  449 
SPDR=Swedish Prescribed Drug Register  450 
NPR=National Patient Register 451 
VAL=Stockholm regional health care data warehouse 452 
CI=Confidence Interval 453 
 454 
 455 
Table 3. Agreement between ‘reported current asthma’ from the questionnaire and SPDR and NPR in the 456 
National cohort, n=18725 457 
 458 
Questionnair
e, q Registers, r 
Overall 
agreement 
%(n) 
q+r-  
n 
q-r+ 
n 
q+r+  
n 
q-r-  
n Kappa (95% CI) 
 'Reported 
current asthma' 
(questionnaire) 
‘Register-based 
current asthma’, 
Asthma defined by 
dispensed 
medications (SPDR)a 
or a diagnosis from 
NPR with at least one 
dispensed medication 
(any) or a diagnosis in 
the last: 
      
 
6m 
95.50 
(17814/18653)  671  168  658  17156 0.59     (0.56-0.61) 
 
12m 
95.94 
(17896/18653) 
 
472 
 
285  857  17039 0.67     (0.65-0.69) 
 
18m 
96.05 
(15873/16526)  314  339  846  15027 0.70      (0.68-0.72) 
 
24m 
95.76 
(13946/14563)  225  392  799  13147 0.70      (0.68-0.72) 
 'Reported 
current asthma' 
(questionnaire) 
‘Register-based 
current asthma’, 
Asthma defined by 
dispensed 
medications (SPDR)a 
or a diagnosis from 
NPR with at least one 
dispensed medication 
in the last: 
      
 
6m 
95.30 
(17777/18653)  726  150  603  17174 0.56      (0.53-0.58) 
 
12m 
95.78 
(17865/18653)  522  266  807  17058 0.65      (0.63-0.67) 
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18m 
96.00 
(15865/16526)  347  314  813  15052 0.69     (0.67-0.71) 
 
24m 
95.76 
(13945/14563)  249  369  775  13170 0.69     (0.67-0.72) 
a=Asthma medication of ≥ 2 dispenses of ICS and/or LTRA and/or B2-ICS independent of time between and/or ≥ 3 dispenses of 459 
ICS and/or LRTA and/or B2-ICS and/or B2 within a 12 month period (prior to the date of the interview  460 
CI=Confidence Interval 461 
SPDR=Swedish Prescribed Drug Register 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
Table 4. Agreement between ’reported asthma medications’ from the questionnaire and SPDR in the National cohort, n=18725 471 
Questionnaire, q Registers, r 
Overall 
agreement % 
(n) 
q+r-  
n 
q-r+ 
n 
q+r+  
n 
q-r-  
n 
Kappa     
(95% CI) 
‘Reported asthma 
medications’ 
(Questionnaire)a 
current 
‘Register-based asthma 
medications’, At least 
one asthma medication 
dispenses (SPDR)b in the 
last: 
      
 
6 m 
79.49 
(1120/1409)  215  74  277  843 
0.52       
(0.47-0.56) 
 
12m 
80.48 
(1134/1409)  137  138  355  779 
0.57       
(0.53-0.62) 
 
18m 
80.13 
(1129/1409)  83  197  409  720 
0.59       
(0.54-0.63) 
 
24m 
77.93 
(1098/1409)  59  252  433  665 
0.55       
(0.52-0.60) 
a=This question was added in 2010, in total n=9860 answered the questionnaire after this timepoint 472 
b=Swedish Prescribed Drug Register (SPDR) 473 
CI=Confidence Interval 474 
 475 
